Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
How would you treat a patient with a post prostatectomy biochemical and pelvic nodal recurrence with a BLM mutation?
Related Questions
What time frame, number of PSAs, and calculator do you use for calculating PSA doubling times?
With the recent BART, trial how would you manage a positive ureter margin that is now part of the urostomy?
Do you add ADT to RT for a patient with intermediate-risk prostate cancer with discordant Decipher and ArteraAI results?
What is the rationale for the recent change in the NCCN criteria for very high risk prostate cancer?
What is your radiation approach/details for regionally involved prostate cancer (N1)?
How would you treat an isolated urothelial cancer local recurrence abutting the duodenum?
What are your top takeaways in GU Cancers from ASCO 2025?
Do you recommend neoadjuvant 177Lu-PNT2002 followed by MDT per the LUNAR trial as your preferred treatment approach for oligorecurrent prostate cancer, as opposed to MDT and PSMA-radioligand therapy used as temporally separate treatments?
How do you interpret nodes with minimal increased uptake on PSMA PET in prostate cancer?
What SBRT dose would you give to a single external iliac lymph node recurrence (1 cm size) for a patient previously treated with salvage radiation to the pelvis?
